Poorly differentiated neuroendocrine carcinomas of the pancreas: A clinicopathologic analysis of 44 cases

American Journal of Surgical Pathology

Volumn 38, Issue 4, 2014, Pages 437-447

  Basturk, Olca ^a   Tang, Laura ^a   Hruban, Ralph H ^b   Adsay, Volkan ^d   Yang, Zhaohai ^e   Krasinskas, Alyssa M ^f   Vakiani, Efsevia ^a   La Rosa, Stefano ^o   Jang, Kee Taek ^p   Frankel, Wendy L ^g   Liu, Xiuli ^h   Zhang, Lizhi ⁱ   Giordano, Thomas J ^j   Bellizzi, Andrew M ^k   Chen, Jey Hsin ^l   Shi, Chanjuan ^m   Allen, Peter ^a   Reidy, Diane L ^a   Wolfgang, Christopher L ^b,c   Saka, Burcu ^d   Rezaee, Neda ^b,c   Deshpande, Vikram ⁿ   Klimstra, David S ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Sol Goldman Pancreatic Cancer Research Center   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PENNSYLVANIA STATE UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^l INDIANA UNIVERSITY   (United States)

^m VANDERBILT UNIVERSITY   (United States)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^o OSPEDALE DI CIRCOLO   (Italy)

^p Sungkyunkwan University   (South Korea)

more..

Author keywords

Carcinoma; High grade; Large cell; Neuroendocrine; Pancreas; Poorly differentiated; Small cell

Indexed keywords

ADULT; AGED; CARCINOMA; CELL DIFFERENTIATION; CONFERENCE PAPER; DISEASE COURSE; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; CELL DIFFERENTIATION; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; YOUNG ADULT;

EID: 84897027158     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000169     Document Type: Conference Paper

References (41)

1. Bosman FT, Carneiro F, HR H, et al. Neuroendocrine tumors of the GI tract. In: Bosman FT, et al, ed. WHO Classification of Tumors of Digestive System. Lyon: WHO Press; 2010:322-326.
2. Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum. 2004;47:163-169.
3. Brenner B, Tang LH, Klimstra DS, et al. Small-cell carcinomas of the gastrointestinal tract: A review. J Clin Oncol. 2004;22:2730-2739.
4. Travis WD, Brambilla E, Mü ller-Hermelink HK, et al. Pathology and genetics of tumours of the lung, pleura, thymus and heart. In: Travis WD, Brambilla E, Mü ller-Hermelink HK, eds. World Health Organization Classification of Tumours. Lyon: IARC Publications; 2004.
5. Lee SS, Lee JL, Ryu MH, et al. Extrapulmonary small cell carcinoma: Single center experience with 61 patients. Acta Oncol. 2007;46:846-851.
6. Faggiano A, Sabourin JC, Ducreux M, et al. Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: Diagnostic and prognostic features. Cancer. 2007;110:265-274.
7. Kang H, O'Connell JB, Leonardi MJ, et al. Rare tumors of the colon and rectum: A national review. Int J Colorectal Dis. 2007;22:183-189.
8. Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32:719-731.
9. Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev. 2009;35:228-236.
10. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21:1794-1803.
11. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol. 2013;24:152-160.
12. Corrin B, Gilby ED, Jones NF, et al. Oat cell carcinoma of the pancreas with ectopic ACTH secretion. Cancer. 1973;31:1523-1527.
13. Reyes CV, Wang T. Undifferentiated small cell carcinoma of the pancreas: A report of five cases. Cancer. 1981;47:2500-2502.
14. Hobbs RD, Stewart AF, Ravin ND, et al. Hypercalcemia in small cell carcinoma of the pancreas. Cancer. 1984;53:1552-1554.
15. Morant R, Bruckner HW. Complete remission of refractory small cell carcinoma of the pancreas with cisplatin and etoposide. Cancer. 1989;64:2007-2009.
16. O'Connor TP, Wade TP, Sunwoo YC, et al. Small cell undifferentiated carcinoma of the pancreas. Report of a patient with tumor marker studies. Cancer. 1992;70:1514-1519.
17. Chetty R, Clark SP, Pitson GA. Primary small cell carcinoma of the pancreas. Pathology. 1993;25:240-242.
18. Ordonez NG, Cleary KR, Mackay B. Small cell undifferentiated carcinoma of the pancreas. Ultrastruct Pathol. 1997;21:467-474.
19. Hruban R, Pitman MB, Klimstra DS. Tumors of the pancreas. In: Silverberg SG, ed. AFIP Atlas of Tumor Pathology. Washington, DC: American Registry of Pathology; 2007.
20. Iwasa S, Morizane C, Okusaka T, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010;40:313-318.
21. Basturk O, Yang Z, Tang LH, et al. Increased (>20%) Ki67 proliferation index in morphologically well differentiated pancreatic neuroendocrine tumors (PanNETs) correlates with decreased overall survival (abstract). Mod Pathol. 2013;26(2S):423A.
22. Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36:173-184.
23. Nassar H, Albores-Saavedra J, Klimstra DS. High-grade neuroendocrine carcinoma of the ampulla of vater: A clinicopathologic and immunohistochemical analysis of 14 cases. Am J Surg Pathol. 2005;29:588-594.
24. Bagci P, Ohike N, Dursun N, et al. Comparative analysis of different counting methodologies for Ki-67 in pancreatic neuroendocrine tumors (abstract). Mod Pathol. 2012;25:441A.
25. Stelow EB, Shaco-Levy R, Bao F, et al. Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. Am J Surg Pathol. 2010;34:510-518.
26. Edge S, Byrd DR, Campton CC, et al. AJCC Cancer Staging Manual. New York: Springer; 2010.
27. Couvelard A, Scoazec JY. A TNM classification for digestive endocrine tumors of midgut and hindgut: Proposals from the European Neuroendocrine Tumor Society (ENETS). Ann Pathol. 2007;27:426-432.
28. Wang DS, Zhang DS, Qiu MZ, et al. Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas. Tumour Biol. 2011;32:697-705.
29. Araujo PB, Cheng S, Mete O, et al. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PLoS One. 2013;8:e61538.
30. Yang Z, Tang LH, Klimstra DS. Gastroenteropancreatic neuroendocrine neoplasms: Historical context and current issues. Semin Diagn Pathol. 2013;30:186-196.
31. Klimstra DS, Heffess CS, Oertel JE, et al. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol. 1992;16:815-837.
32. Klimstra DS, Rosai J, Heffess CS. Mixed acinar-endocrine carcinomas of the pancreas. Am J Surg Pathol. 1994;18:765-778.
33. Movahedi-Lankarani S, Hruban RH, Westra WH, et al. Primitive neuroectodermal tumors of the pancreas: A report of seven cases of a rare neoplasm. Am J Surg Pathol. 2002;26:1040-1047.
34. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: An analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633-2642.
35. Zee SY, Hochwald SN, Conlon KC, et al. Pleomorphic pancreatic endocrine neoplasms: A variant commonly confused with adenocarcinoma. Am J Surg Pathol. 2005;29:1194-1200.
36. Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010;39:799-800.
37. Tang L, Shia J, Vakiani E, et al. High grade transformation of differentiatedneuroendocrineneoplasms (NENs) of the enteropancreatic system-A unique entity distinct from de-novo high grade neuroendocrine carcinoma (HGNECa) in pathogenesis and clinical behavior (abstract #622). Mod Pathol. 2008;21(S1):137A.
38. Basturk O, Klimstra DS. Acinar cell carcinoma of the pancreas and related neoplasms: A review. Diagn Histopathol. 2012;18:8-16.
39. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg. 1996;62:798-809; discussion 809-10.
40. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227-232.
41. Motojima K, Furui J, Terada M, et al. Small cell carcinoma of the pancreas and biliary tract. J Surg Oncol. 1990;45:164-168.